Haematology
MK3543-006
A phase 3, randomized, open-label, active-comparator-controlled clinical study to evaluate the safety and efficacy of bomedemstat (MK-3543/IMG-7289) versus best available therapy (BAT) in participants with essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea.
Trial overview
Description
A phase 3, randomized, open-label, active-comparator-controlled clinical study to evaluate the safety and efficacy of bomedemstat (MK-3543/IMG-7289) versus best available therapy (BAT) in participants with essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea.
Study details
For detailed information on this trial, please click here
Trial status
Due to open June 2025
Location
Principal Investigator
Dr Pratap Neelakatan
You are leaving our website
You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.